This experimental evidence led to the conclusion that lovastatin enhances the sensitivity of colon cancer cells to radiotherapy by intensifying the activation of the cGAS–STING pathway, facilitating the type I IFN signaling and boosting the infiltration and cytotoxicity of CD8+ T cells. The gene discussed is STING1; the disease is malignant colon neoplasm.